Last reviewed · How we verify

Xolair Prefilled Syringe

Kashiv BioSciences, LLC · Phase 3 active Small molecule

Xolair Prefilled Syringe is a Monoclonal antibody (anti-IgE) Small molecule drug developed by Kashiv BioSciences, LLC. It is currently in Phase 3 development for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Allergic rhinitis (in some formulations).

Xolair (omalizumab) is a monoclonal antibody that binds to circulating immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.

Xolair (omalizumab) is a monoclonal antibody that binds to circulating immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation. Used for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Allergic rhinitis (in some formulations).

At a glance

Generic nameXolair Prefilled Syringe
SponsorKashiv BioSciences, LLC
Drug classMonoclonal antibody (anti-IgE)
TargetImmunoglobulin E (IgE)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

By sequestering free IgE, omalizumab reduces the amount of IgE available to cross-link FcεRI receptors on mast cells and basophils. This prevents degranulation and release of inflammatory mediators (histamine, tryptase, leukotrienes) that drive allergic symptoms. The prefilled syringe formulation provides a convenient subcutaneous delivery method for this anti-IgE therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Xolair Prefilled Syringe

What is Xolair Prefilled Syringe?

Xolair Prefilled Syringe is a Monoclonal antibody (anti-IgE) drug developed by Kashiv BioSciences, LLC, indicated for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Allergic rhinitis (in some formulations).

How does Xolair Prefilled Syringe work?

Xolair (omalizumab) is a monoclonal antibody that binds to circulating immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.

What is Xolair Prefilled Syringe used for?

Xolair Prefilled Syringe is indicated for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Allergic rhinitis (in some formulations).

Who makes Xolair Prefilled Syringe?

Xolair Prefilled Syringe is developed by Kashiv BioSciences, LLC (see full Kashiv BioSciences, LLC pipeline at /company/kashiv-biosciences-llc).

What drug class is Xolair Prefilled Syringe in?

Xolair Prefilled Syringe belongs to the Monoclonal antibody (anti-IgE) class. See all Monoclonal antibody (anti-IgE) drugs at /class/monoclonal-antibody-anti-ige.

What development phase is Xolair Prefilled Syringe in?

Xolair Prefilled Syringe is in Phase 3.

What are the side effects of Xolair Prefilled Syringe?

Common side effects of Xolair Prefilled Syringe include Injection site reaction, Headache, Upper respiratory tract infection, Arthralgia, Fatigue, Anaphylaxis.

What does Xolair Prefilled Syringe target?

Xolair Prefilled Syringe targets Immunoglobulin E (IgE) and is a Monoclonal antibody (anti-IgE).

Related